Skip to: Content
Skip to: Site Navigation
Skip to: Search

August 29, 2008 11:59:32 PM CDT

Learn about Newser Points »

Stories related to: Genentech

Stories

7 Stories

  • July 2008

    • Roche Makes Genentech Takeover Bid

      Wall Street Journal  |  Jul 21, 08 6:55 AM CDT

      Roche Makes Genentech Takeover Bid

      (Newser) - Swiss pharmaceutical company Roche today offered $43.7 billion for the outstanding shares of Genentech, the San Francisco-based biotech firm in which Roche already owns a 55.9% stake, the Wall Street Journal reports. The $89-a-share offer is the latest in a series of big pharma companies, whose new drug development has been lagging, stepping up investment in the more productive biotech sector. More »

      Tags

      mergers and acquisitions  • takeover  • Genentech  • Roche Holding

  • April 2008

    • Cancer Drug Sales Push Genentech Profits Up 12%

      Wall Street Journal  |  Apr 11, 08 8:28 AM CDT

      Cancer Drug Sales Push Genentech Profits Up 12%

      (Newser) - Biotech firm Genentech said sales of its blockbuster cancer drug Avastin fueled a first-quarter profit increase of 12%, reports the Wall Street Journal, but the $600 million in sales was below analysts’ projected $622 million, causing some to grumble the drug may have reached a sales plateau. Genentech stock edged up 0.3% in after-hours trading. More »

      Tags

      FDA  • breast cancer  • corporate earnings  • Genentech  • Avastin  • Roche Holding

  • February 2008

    • FDA Clears Avastin for Breast Cancer

      Associated Press  |  Feb 22, 08 6:06 PM CST

      FDA Clears Avastin for Breast Cancer

      (Newser) - The FDA has approved a drug currently prescribed to treat lung and colon cancer for use on breast cancer patients, the AP reports. The decision defies the advice of the FDA's own advisory panel, which recommended that Avastin not be used to treat breast cancer on the grounds that it slowed tumor growth without increasing life expectancy. Patient advocates are thrilled with the ruling. More »

      Tags

      FDA  • breast cancer  • lung cancer  • colon cancer  • tumors  • Genentech  • mortality  • Avastin

    • Fortune Names Top Employers

      CNN  |  Feb 3, 08 5:32 AM CST

      Fortune Names Top Employers

      (Newser) - Thinking of a career move? Fortune Magazine has released its 100 best employers for 2008 list—and the top 10 are: Google (Mountain View, CA) Quicken Loans (Livonia, MI) Wegmans Food Markets (Rochester, NY) Edward Jones (St. Louis, MO) Genentech (South San Francisco, CA) More »

      Tags

      list  • Google  • Starbucks  • Cisco Systems  • Genentech  • Fortune  • Wegmans

  • January 2008

    • Street Yawns at Genentech Quarterlies

      Associated Press  |  Jan 15, 08 11:09 AM CST

      Street Yawns at Genentech Quarterlies

      (Newser) - Drug maker Genentech – struggling with near-flat sales of its two premier drugs, Avastin and Rituxan – managed to outperform analyst’s fourth quarter expectations – barely, reports the Associated Press. The one-time biotech uber star, which recorded phenomenal growth in each of the two previous years, showed only a 6.4% increase in profits on sales that rose 9% in the quarter. More »

      Tags

      earnings reports  • pharmaceutical  • biotechnology  • Genentech  • Avastin

  • December 2007

    • FDA Panel Rejects Breast Cancer Drug

      Wall Street Journal  |  Dec 5, 07 4:34 PM CST

      FDA Panel Rejects Breast Cancer Drug

      (Newser) - An FDA panel rejected a drug to treat advanced breast cancer by 5-to-4 vote, the Wall Street Journal reports. The drug Avastin is already used to treat colon and lung cancer, but the panel said it did not have sufficient data to weigh the risks and benefits of using the drug to treat breast cancer. More »

      Tags

      FDA  • breast cancer  • Genentech  • Avastin

  • August 2007

    • Biotech Giant Slashes Jobs

      Wall Street Journal  |  Aug 16, 07 1:34 AM CDT

      Biotech Giant Slashes Jobs

      (Newser) - Biotech giant Amgen is slashing spending by $1.9 billion by cutting up to 14 percent of its workforce— 2,600 jobs—and closing some production facilities. The restructuring was triggered by plummeting sales of the company's anemia drug Aranesp. The shake up demonstrates that biotech operations are not immune to the problems that plague traditional drug companies, the Wall Street Journal reports. More »

      Tags

      biotechnology  • Genentech  • restructuring  • Roche Holding  • Amgen

7 Stories

Today's Most Popular

Premium Articles from HighBeam

Find more articles like this

What is Newser?

2008 Codie Finalist

Newser gives you more news in less time. We search for the best and most important stories all over the web, read them for you, and deliver concise and sharp summaries—along with links to the full text. Newser provides a way to stay on top of an ever-expanding horizon of news and opinion—politics, sports, business, trends, technology, personalities, crimes, and controversies. Newser keeps you not just better informed, but, with our signature graphic interface and smart condensed format, more enjoyably informed.

Learn more »